Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People whose physical functioning and activity level meets a specific standard, rated 0 or 1 on a medical scale used to measure how well a person can carry out daily activities (confirm with trial site)
• People with multiple myeloma who have already received at least 3 different treatment regimens, including at least one treatment from each of three specific drug types: anti-CD38 antibodies, immunomodulatory drugs (IMiDs), and proteasome inhibitors — and whose disease has continued to grow or spread after their most recent treatment
• People whose disease is measurable in a way that allows doctors to track treatment response (confirm with trial site)
• People whose blood counts, liver, and kidney are functioning at an adequate level as defined by the trial (confirm with trial site)

Who may not be able to join:

• People diagnosed with plasma cell leukemia, primary systemic light-chain amyloidosis, Waldenström macroglobulinemia, or POEMS syndrome
• People who have received any cancer treatment within either 28 days before the first study drug dose, or within 5 half-lives of their previous treatment — whichever period is shorter
• People who have had a donor stem cell transplant within the past 6 months, or their own stem cell transplant within the past 12 weeks
• People who have taken steroid medications above a certain dose within 72 hours before the start of the study drug (confirm with trial site)
• People with known involvement of multiple myeloma in the brain or nervous system, a suspected or known condition called progressive multifocal leukoencephalopathy, a history of a brain or nervous system disorder, or a seizure within the past 12 months
• People who have received a live or live-attenuated vaccine within 28 days before the first study drug dose
• People who have received a COVID-19 vaccine within 1 week before the planned start of the study medication
• People who have had a blood disorder called myelodysplastic syndrome, or another cancer in the past 3 years — with some exceptions such as certain skin cancers, early-stage thyroid cancer, low-risk early prostate cancer, or carcinoma in situ (confirm with trial site)
• People with significant heart or cardiovascular disease as defined by the trial (confirm with trial site)
• People with uncontrolled HIV, Hepatitis B, Hepatitis C, or other uncontrolled infections such as CMV
• People with a known allergy to both allopurinol and rasburicase (two medications used to manage certain side effects)

Important: Always verify eligibility with the trial site directly before applying.